GlassScriptPhysician profile
Laurie A Womack
NPI 1942392618
$5,220.85
in general payments reported to CMS, 2019-2025
29 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $226 · 2021: $992 · 2022: $1,368 · 2023: $839 · 2024: $1,068 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,375.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,553.89 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $340.53 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Novartis Pharmaceuticals Corporation | $316.98 | 2021-2025 | |
| Novo Nordisk INC | $299.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $217.21 | 2019-2024 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.42 | 2019-2024 | Tradjenta, Jardiance, Synjardy |
| Allergan, INC. | $131.21 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.20 | 2022-2024 | |
| Glaxosmithkline, LLC. | $118.03 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Janssen Pharmaceuticals, INC | $109.77 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $105.29 | 2021-2024 | Capvaxive, Gardasil, Vaxneuvance |
| Astrazeneca Pharmaceuticals LP | $100.48 | 2019-2024 | Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $88.85 | 2022 | |
| Astellas Pharma US INC | $77.90 | 2019-2024 | Veozah |
| Amarin Pharma, INC. | $70.39 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $66.50 | 2023-2024 | Gemtesa |
| Medtronic, INC. | $39.59 | 2025 | Inceptiv |
| Pfizer INC. | $38.75 | 2020-2023 | |
| Abbott Laboratories | $35.88 | 2021-2023 | Freestyle Libre 2 |
| Dexcom, INC. | $32.88 | 2022-2025 | Dexcom G6 Transmitter |
| Abiomed | $32.74 | 2024 | Impella |
| Eisai INC. | $32.43 | 2021 | |
| Sunovion Pharmaceuticals INC. | $32.36 | 2021 | |
| Supernus Pharmaceuticals, INC. | $26.13 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $17.40 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $14.16 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.08 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $12.79 | 2021 | |
| Mylan Specialty L.P. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Womack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.